Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis
Clinical Scorecard: Evaluating the Safety and Effectiveness of Advanced Combination Treatments for Adult Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD)
Key Mechanisms
Advanced combination therapy (ACT) using biologic agents and small molecules.
Target Population
Adults with refractory inflammatory bowel disease.
Care Setting
Clinical practice for IBD management.
Key Highlights
Low rates of serious adverse events (SAEs) reported with ACT.
Evidence derived from 52 studies involving 2022 participants.
High level of treatment failures remains a concern in IBD.
Substantial heterogeneity and very low certainty of evidence noted.
Cautious use of ACT is recommended for selected patients.
Guideline-Based Recommendations
Diagnosis
Diagnosis of IBD should be confirmed through clinical, endoscopic, and histological evaluations.
Management
ACT may be considered for patients with refractory IBD.
Monitoring & Follow-up
Patients receiving ACT should be monitored for adverse events and treatment efficacy.
Risks
Potential for serious adverse events and treatment discontinuations.
Patient & Prescribing Data
Adults with refractory IBD.
ACT involves combinations of biologics and small molecules, with varying efficacy and safety profiles.
Clinical Best Practices
Utilize a multidisciplinary approach for managing IBD.
Consider patient-specific factors when prescribing ACT.
Encourage participation in adequately powered trials for better safety data.
